Trial Profile
ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms ARIES1; ARIES2
- Sponsors Gilead Sciences; Myogen
- 30 May 2008 Results published in Circulation.
- 30 May 2008 Status changed from in progress to completed.
- 21 May 2008 Results presented at ATS 2008.